HUP0203167A3 - Peptidic substances, their preparations and their use as complement protease inhibitors - Google Patents

Peptidic substances, their preparations and their use as complement protease inhibitors

Info

Publication number
HUP0203167A3
HUP0203167A3 HU0203167A HUP0203167A HUP0203167A3 HU P0203167 A3 HUP0203167 A3 HU P0203167A3 HU 0203167 A HU0203167 A HU 0203167A HU P0203167 A HUP0203167 A HU P0203167A HU P0203167 A3 HUP0203167 A3 HU P0203167A3
Authority
HU
Hungary
Prior art keywords
preparations
protease inhibitors
complement protease
peptidic substances
peptidic
Prior art date
Application number
HU0203167A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HUP0203167A2 publication Critical patent/HUP0203167A2/hu
Publication of HUP0203167A3 publication Critical patent/HUP0203167A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
HU0203167A 1999-04-09 2000-03-28 Peptidic substances, their preparations and their use as complement protease inhibitors HUP0203167A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19915930 1999-04-09
PCT/EP2000/002710 WO2000061608A2 (de) 1999-04-09 2000-03-28 Niedermolekulare inhibitoren von komplementproteasen

Publications (2)

Publication Number Publication Date
HUP0203167A2 HUP0203167A2 (hu) 2003-02-28
HUP0203167A3 true HUP0203167A3 (en) 2003-09-29

Family

ID=7903946

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203167A HUP0203167A3 (en) 1999-04-09 2000-03-28 Peptidic substances, their preparations and their use as complement protease inhibitors

Country Status (22)

Country Link
US (1) US6683055B1 (hu)
EP (1) EP1169338B1 (hu)
JP (1) JP4489976B2 (hu)
KR (1) KR20010108477A (hu)
CN (1) CN1351609A (hu)
AT (1) ATE281466T1 (hu)
AU (1) AU4111700A (hu)
BG (1) BG105978A (hu)
BR (1) BR0009678A (hu)
CA (1) CA2369378A1 (hu)
CZ (1) CZ20013577A3 (hu)
DE (1) DE50008510D1 (hu)
HK (1) HK1045846A1 (hu)
HU (1) HUP0203167A3 (hu)
IL (1) IL145771A0 (hu)
MX (1) MXPA01010114A (hu)
NO (1) NO20014876L (hu)
PL (1) PL351441A1 (hu)
SK (1) SK14232001A3 (hu)
TR (1) TR200102913T2 (hu)
WO (1) WO2000061608A2 (hu)
ZA (2) ZA200107890B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355810A (zh) * 1999-04-09 2002-06-26 巴斯福股份公司 凝血酶抑制剂的前体药物
JP2004506648A (ja) * 2000-08-11 2004-03-04 コーバス　インターナショナル，　インコーポレイテッド ウロキナーゼおよび血管形成の非共有結合性インヒビター
ATE517910T1 (de) * 2000-08-11 2011-08-15 Wilex Ag NICHT-KOVALENTE INHIBITOREN VON UROKINASE UND BLUTGEFÄßBILDUNG
WO2003070229A2 (de) * 2002-02-22 2003-08-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von proteinaseinhibitoren zur behandlung von autoimmunerkrankungen
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
EP2266606B1 (en) * 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
TW200519105A (en) * 2003-10-20 2005-06-16 Lg Life Science Ltd Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
CN1304568C (zh) * 2004-07-05 2007-03-14 中国人民解放军第二军医大学 新型人补体C1r样丝氨酸蛋白酶类似物,其编码序列及用途
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
CA2601777A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7385066B2 (en) * 2005-03-16 2008-06-10 Janssen Pharmaceutica N.V. Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions
EP2282735B1 (en) 2008-04-21 2019-01-16 Signum Biosciences, Inc. Pp2a modulators for treating alzheimer, parkinson, diabetes
CN102464701B (zh) * 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
US9079929B2 (en) 2011-10-14 2015-07-14 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
LT2766346T (lt) 2011-10-14 2017-06-12 Bristol-Myers Squibb Company Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
DK2906551T3 (en) 2012-10-12 2018-05-22 Bristol Myers Squibb Co CRYSTALLIC FORMS OF A FACTOR XIA INHIBITOR
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
WO2015116886A1 (en) 2014-01-31 2015-08-06 Bristol-Myers Squibb Company Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (hu) 2014-01-31 2018-03-10
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
AU2020245434A1 (en) * 2019-03-22 2021-09-30 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738910A1 (de) 1987-11-17 1989-05-24 Basf Ag Tributylammoniumsalz von 1,1-dicyano-2-hydroxy-3-chlorprop-1-en, ein verfahren zu seiner herstellung sowie ein verfahren zur herstellung von 2-amino-4-chlor-3-cyano-5-formylthiophen
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
DE4443390A1 (de) * 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
KR19980702112A (ko) 1995-02-10 1998-07-15 페라 스타르크,요헨 카르크 트롬빈 억제제
MX9706069A (es) * 1995-02-17 1997-10-31 Basf Ag Nuevos inhibidores de la trombina.
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
DE19632773A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
DE19632772A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
DE19635674A1 (de) 1996-09-03 1998-03-05 Basf Ag Verfahren zur Herstellung von Amidinen
US6653340B1 (en) * 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
JP2002501081A (ja) * 1998-01-26 2002-01-15 ビーエーエスエフ アクチェンゲゼルシャフト トロンビンインヒビター
EP1049673A1 (de) * 1998-01-26 2000-11-08 Basf Aktiengesellschaft Heterocyclische amidine als kallikrein protease inhibitoren

Also Published As

Publication number Publication date
BG105978A (bg) 2002-07-31
ATE281466T1 (de) 2004-11-15
AU4111700A (en) 2000-11-14
JP2002542164A (ja) 2002-12-10
IL145771A0 (en) 2002-07-25
ZA200107978B (en) 2003-03-26
PL351441A1 (en) 2003-04-22
NO20014876L (no) 2001-12-04
ZA200107890B (en) 2003-11-26
HK1045846A1 (zh) 2002-12-13
MXPA01010114A (es) 2002-07-30
SK14232001A3 (sk) 2002-06-04
CA2369378A1 (en) 2000-10-19
JP4489976B2 (ja) 2010-06-23
EP1169338B1 (de) 2004-11-03
BR0009678A (pt) 2002-01-22
CN1351609A (zh) 2002-05-29
DE50008510D1 (de) 2004-12-09
KR20010108477A (ko) 2001-12-07
HUP0203167A2 (hu) 2003-02-28
EP1169338A2 (de) 2002-01-09
US6683055B1 (en) 2004-01-27
WO2000061608A2 (de) 2000-10-19
TR200102913T2 (tr) 2002-01-21
CZ20013577A3 (cs) 2002-07-17
WO2000061608A3 (de) 2001-01-11
NO20014876D0 (no) 2001-10-08

Similar Documents

Publication Publication Date Title
HUP0203167A3 (en) Peptidic substances, their preparations and their use as complement protease inhibitors
HUP0200347A3 (en) N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use
HUP0100669A3 (en) Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
HUP0000427A3 (en) Benzamidoaldehydes and their use as cysteine protease inhibitors
ZA200204390B (en) Caspase inhibitors and uses thereof.
HUP0300720A3 (en) Serine protease inhibitors, pharmaceutical compositions containing them and their use
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
PL340560A1 (en) Heteroaryl aminoguanidines and alkoxyguanidines and their application as protease inhibitors
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
HUP9900390A3 (en) Serine protease inhibitors, and pharmaceutical compositions containing them
AU2002223313A1 (en) Protease inhibitors and their pharmaceutical uses
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU6975001A (en) Metalloprotease peptide substrates and methods
HUP0104623A3 (en) Cyclosporin solution, pharmaceutical composition comprising thereof and its use
IL146940A0 (en) Novel calpains and their use
ZA9810833B (en) Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors.
AUPP899699A0 (en) Peptides, agents and methods
AU2002225370A1 (en) Novel peptides and activities thereof
IL145152A0 (en) Novel protein and its use
GB9926347D0 (en) Virulence gene and protein, and their use
GB9926350D0 (en) Virulence gene and protein, and their use
GB9926356D0 (en) Virulence gene and protein, and their use
GB9926340D0 (en) Virulence gene and protein, and their use
GB9930469D0 (en) Virulence gene and protein,and their use